Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares.
Gwenn S SmithClifford I WorkmanHillary ProtasYi SuAlena SavonenkoHiroto KuwabaraNeda F GouldMichael KrautJin Hui JooAyon NandiDimitrios AvramopoulosEric M ReimanKewei ChenPublished in: Translational psychiatry (2021)
Depression in late-life is associated with increased risk of cognitive decline and development of all-cause dementia. The neurobiology of late-life depression (LLD) may involve both neurochemical and neurodegenerative mechanisms that are common to depression and dementia. Transgenic amyloid mouse models show evidence of early degeneration of monoamine systems. Informed by these preclinical data, the hypotheses were tested that a spatial covariance pattern of higher beta-amyloid (Aβ) and lower serotonin transporter availability (5-HTT) in frontal, temporal, and parietal cortical regions would distinguish LLD patients from healthy controls and the expression of this pattern would be associated with greater depressive symptoms. Twenty un-medicated LLD patients who met DSM-V criteria for major depression and 20 healthy controls underwent PET imaging with radiotracers for Aβ ([11C]-PiB) and 5-HTT ([11C]-DASB). A voxel-based multi-modal partial least squares (mmPLS) algorithm was applied to the parametric PET images to determine the spatial covariance pattern between the two radiotracers. A spatial covariance pattern was identified, including higher Aβ in temporal, parietal and occipital cortices associated with lower 5-HTT in putamen, thalamus, amygdala, hippocampus and raphe nuclei (dorsal, medial and pontine), which distinguished LLD patients from controls. Greater expression of this pattern, reflected in summary 5-HTT/Aβ mmPLS subject scores, was associated with higher levels of depressive symptoms. The mmPLS method is a powerful approach to evaluate the synaptic changes associated with AD pathology. This spatial covariance pattern should be evaluated further to determine whether it represents a biological marker of antidepressant treatment response and/or cognitive decline in LLD patients.
Keyphrases
- depressive symptoms
- cognitive decline
- end stage renal disease
- mild cognitive impairment
- pet imaging
- positron emission tomography
- chronic kidney disease
- ejection fraction
- newly diagnosed
- computed tomography
- peritoneal dialysis
- poor prognosis
- sleep quality
- spinal cord
- prognostic factors
- stem cells
- social support
- cell therapy
- mesenchymal stem cells
- bipolar disorder
- electronic health record
- brain injury
- mouse model
- major depressive disorder
- binding protein
- blood brain barrier
- optical coherence tomography